Sep 21, 2024
New York [US], September 21: When researchers discovered enough proof that a medication used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that affects 1 in 5,000 people worldwide, they decided to terminate an early clinical trial funded by the National Institutes of Health (NIH).
Read More...
Sep 21, 2024
Canberra [Australia], September 21: Australia was on the verge of supporting an international call for Israel to...
Sep 21, 2024
Los Angeles [US], September 21: Early in-person voting sites opened throughout the three states of Virginia, Minnesota...
Sep 21, 2024
Ottawa [Canada], September 21: The Canadian federal government Friday announced new funding for the eradication of polio...
Sep 21, 2024
Sep 21, 2024
Sep 20, 2024
Sep 20, 2024
Sep 20, 2024
